A novel, label-free, pre-equilibrium assay to determine the association and dissociation rate constants of therapeutic antibodies on living cells.

Autor: Janezic EM; Genentech, Inc, South San Francisco, California, USA., Doan A; Genentech, Inc, South San Francisco, California, USA., Mai E; Genentech, Inc, South San Francisco, California, USA., Bravo DD; Genentech, Inc, South San Francisco, California, USA., Wang J; Genentech, Inc, South San Francisco, California, USA., Kim HS; Genentech, Inc, South San Francisco, California, USA., Spiess C; Genentech, Inc, South San Francisco, California, USA., Bewley K; Genentech, Inc, South San Francisco, California, USA., ElSohly A; Genentech, Inc, South San Francisco, California, USA., Liang WC; Genentech, Inc, South San Francisco, California, USA., Koerber JT; Genentech, Inc, South San Francisco, California, USA., Richalet P; BioRevera, LLC, Gorham, Maine, USA., Vanhove M; Marc Vanhove Consultancy, Boncelles, Belgium., Comps-Agrar L; Genentech, Inc, South San Francisco, California, USA.
Jazyk: angličtina
Zdroj: British journal of pharmacology [Br J Pharmacol] 2024 Oct; Vol. 181 (20), pp. 3836-3855. Date of Electronic Publication: 2023 Nov 05.
DOI: 10.1111/bph.16258
Abstrakt: Background and Purpose: Monoclonal antibodies (Ab) represent the fastest growing drug class. Knowledge of the biophysical parameters (k on , k off and K D ) that dictate Ab:receptor interaction is critical during the drug discovery process. However, with the increasing complexity of Ab formats and their targets, it became apparent that existing technologies present limitations and are not always suitable to determine these parameters. Therefore, novel affinity determination methods represent an unmet assay need.
Experimental Approach: We developed a pre-equilibrium kinetic exclusion assay using recent mathematical advances to determine the k on , k off and K D of monoclonal Ab:receptor interactions on living cells. The assay is amenable to all human IgG1 and rabbit Abs.
Key Results: Using our novel assay, we demonstrated for several monoclonal Ab:receptor pairs that the calculated kinetic rate constants were comparable with orthogonal methods that were lower throughput or more resource consuming. We ran simulations to predict the critical conditions to improve the performance of the assays. We further showed that this method could successfully be applied to both suspension and adherent cells. Finally, we demonstrated that k on and k off , but not K D , correlate with in vitro potency for a panel of monoclonal Abs.
Conclusions and Implications: Our novel assay has the potential to systematically probe binding kinetics of monoclonal Abs to cells and can be incorporated in a screening cascade to identify new therapeutic candidates. Wide-spread adoption of pre-equilibrium assays using physiologically relevant systems will lead to a more holistic understanding of how Ab binding kinetics influence their potency.
(© 2023 British Pharmacological Society.)
Databáze: MEDLINE
Externí odkaz: